Lehi, Utah — CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, reported that CEO Ryan Davies discussed the future of the cancer therapeutic industry with Dr. Looper, a life-long researcher in the chemistry field. Ryan Looper, Ph.D., Colorado State...
research News
Santa Barbara, Calif. — CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, today announced that its UCLA research team has created a promising new drug candidate for treating recurrent Ewing sarcoma, a deadly children’s cancer. Ewing sarcoma is a rare...
Strasbourg, France – A new study presented at the European Psychiatric Association Congress 2024 reveals a significant association between prenatal cannabis use disorder (CUD) and an increased risk of neurodevelopmental disorders in offspring, including attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and intellectual disability (ID). Cannabis remains by...
LUND, Sweden – Cantargia (STO:CANTA) (Cantargia AB; Nasdaq Stockholm:CANTA) today reported new data highlighting the potential of the CAN10 antibody, currently in phase I clinical development, as therapy in systemic sclerosis. All signaling systems targeted by CAN10 (IL-1, IL-33 and IL-36) were found to be highly upregulated in patient skin...
San Francisco, California – Grant of up to $11 million will fund a clinical trial at UCSF that uses a smarter new CAR-T guided by precision technology. A type of gene therapy called CAR-T that has extended survival for thousands of patients with leukemia and other blood cancers is being...
Basel, Switzerland – Chimeric antigen receptor (CAR) T-cell therapy represents one of the most significant advancements in modern immunotherapy. Originally developed to treat hematologic malignancies, this approach involves genetically modifying a patient’s T cells to express an artificial receptor capable of recognizing specific tumor antigens. Upon re-infusion, these tailored T...
Among patients with refractory large B cell lymphoma (LBCL), chimeric antigen receptor (CAR)-T cell therapy appears to yield superior long-term clinical outcomes to those seen with standard salvage therapy regimens, according to an analysis published in Blood Advances. Treatments for LBCL, the most common non-Hodgkin lymphoma subtype, have improved over the...
Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated effectiveness and safety in relapsed/refractory multiple myeloma (RRMM), according to a meta-analysis published in the International Journal of Medical Sciences. RRMM treatments have come a long way and have drastically improved overall survival, but the disease remains incurable. CAR-T therapy has led to...
STAMFORD, Conn. — Cara Therapeutics, Inc. today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the Company’s cash runway into 2026, enabling the expected completion of the NP clinical program....
MADISON — A fundamental question about how sugar units are strung together into long carbohydrate chains has also pinpointed a promising way to target new medicines against tuberculosis. Working with components of the tuberculosis bacterium, researchers from the University of Wisconsin-Madison identified an unusual process by which the pathogen builds...